Press Release: UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

Dow JonesFeb 27 08:05 ET

When Can We Expect A Profit From UroGen Pharma Ltd. (NASDAQ:URGN)?

Simply Wall StFeb 27 06:05 ET

UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025

UroGen PharmaFeb 27 00:00 ET

Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?

Yahoo FinanceFeb 25 12:30 ET

H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $64

Moomoo NewsFeb 25 07:33 ET · Ratings

UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference

UroGen PharmaFeb 24 00:00 ET

Express News | As Consideration For Assets, UroGen Issued IconOVir 374,843 Of Its Ordinary Shares, Agreed To One-Time Payment Of $15M Upon Milestones And A Low Single-Digit Royalty Percentage

BenzingaFeb 20 08:04 ET

Express News | UroGen Acquires Assets Relating To ICVB-1042 From IconOVir

BenzingaFeb 20 08:03 ET

UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations

UroGen PharmaFeb 20 00:00 ET

UroGen Pharma Coverage Assumed by Ladenburg Thalmann at Buy

Dow JonesFeb 19 12:27 ET

Ladenburg Thalmann Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $31

Moomoo NewsFeb 19 07:31 ET · Ratings

UroGen Announces Subgroup Analysis Results For ENVISION Study Of UGN-102 In LG-IR-NMIBC; Comparable CR Rates And DOR Observed Across Tumor Burden And Focality Levels

BenzingaFeb 14 14:34 ET

UroGen Announces Results From Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102

UroGen PharmaFeb 14 00:00 ET

Express News | D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target

BenzingaFeb 12 10:16 ET

Insider Sale: Chief Medical Officer of $URGN Sells 1,896 Shares

Quiver QuantitativeFeb 4 12:01 ET

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen PharmaJan 30 00:00 ET

Express News | UroGen Highlights Results From Study On Durability Of Response From Post-Commercialization Of JELMYTO Titled 'Durability of Response of UGN-101: Longitudinal Follow-Up of Multicenter Study'

BenzingaJan 22 08:08 ET

New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population With Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

UroGen PharmaJan 22 00:00 ET

Express News | UroGen Pharma Shares Are Trading Higher After the Company Reported Its ENVISION Trial Results in the February Issue of The Journal of Urology

BenzingaJan 15 08:08 ET

Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

BenzingaJan 14 06:00 ET